Clinical trials
Terminated Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 7 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 30 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 3 |
| National Cancer Institute (NCI) | 3 |
| M.D. Anderson Cancer Center | 2 |
| Masonic Cancer Center, University of Minnesota | 2 |
| University of Massachusetts, Worcester | 2 |
| Beth Israel Deaconess Medical Center | 1 |
| Eli Lilly and Company | 1 |
| Erimos Pharmaceuticals | 1 |
| Exelixis | 1 |
| Gilead Sciences | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 30 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 20 |
| Leukemia, Myeloid, Acute | 17 |
| Myelodysplastic Syndromes | 15 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 9 |
| Blast Crisis | 6 |
| Hodgkin Disease | 5 |
| Primary Myelofibrosis | 5 |
| Anemia, Refractory, with Excess of Blasts | 4 |
| Leukemia | 4 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.